title: [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
abstract: When aprotinin is used during cardiopulmonary bypass, there is a prolongation of the activated clotting time (ACT), which is used to monitor heparinization. The aim of this study was to observe the effects of aprotinin and heparin on whole blood ACT and whole blood prothrombin time (BPT). The results showed that when kaolin was used as the contact activator, the intrinsic clotting system was also inhibited by aprotinin, the observed ACTs with various dose aprotinin and concomitant heparin were significantly prolonged (Q = 0.757, P < 0.01). There was a dose-dependent prolongation of BPT by heparin (r = 0.985, P < 0.01). However, the heparin-mediated prolongation of BPT was not enhanced by aprotinin. The authors conclude that aprotinin prolongs heparinized whole blood activated clotting time but was not whole blood prothrombin time.
authors.affiliation: Department of Physiology, Hunan Medical University, Changsha.
authors.forename: Z
authors.initials: Z
authors.lastname: Wen
authors.forename: F
authors.initials: F
authors.lastname: Zhu
authors.forename: X
authors.initials: X
authors.lastname: He
authors.forename: S
authors.initials: S
authors.lastname: Xiong
authors.forename: S
authors.initials: S
authors.lastname: He
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000494:pharmacology*; D007611:Aprotinin / Q000494:pharmacology*; D005260:Female; D006490:Hemostatics / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D008297:Male; D011517:Prothrombin Time; D014914:Whole Blood Coagulation Time
chemical_list: D000925:Anticoagulants; D006490:Hemostatics; D006493:Heparin; D007611:Aprotinin